Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01810952 · ClinicalTrials.gov registry record · Phase 4
The Management of Glucocorticoid-Induced Hyperglycemia in Hospitalized Patients
A Phase 4 study of Diabetes Mellitus and Hyperglycemia, sponsored by Baylor College of Medicine.
- Completed
- Registry status
- Phase 4
- Development phase
- 37
- Enrollment target
- 1
- Study location
NCT01810952: Completed Phase 4 study of Diabetes Mellitus and Hyperglycemia, sponsored by Baylor College of Medicine.
NCT01810952 is a Phase 4 study of Diabetes Mellitus and Hyperglycemia that has completed, run by Baylor College of Medicine. The registered enrollment target is 37 participants, below the 1,867-participant average among 208 other Diabetes Mellitus trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01810952, a Phase 4 study of Diabetes Mellitus and Hyperglycemia, has completed, sponsored by Baylor College of Medicine.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 37 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigators hypothesize that includes patient weight and glucocorticoid dose can be used to safely initiate insulin treatment in diabetic/hyperglycemic patients who are to be treated with pharmacological doses of glucocorticoids.
Primary Outcome
Most patients had 4 and all patients had at least 2 readings each day. Average daily glucose values were determined for each participant, then averaged for each Arm."
Conditions Studied
Interventions
- DRUG Glargine insulin
- DRUG Lispro insulin
- DRUG NPH Insulin
Study Locations (1)
Texas
- St. Luke's Episcopal Hospital - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2010-09 |
| Est. Completion | 2013-09 |
| Phase | Phase 4 |
What the finished NCT01810952 record still lists
NCT01810952 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 37 participants, a relatively small participant target, below the 1,867-participant average among 208 other Diabetes Mellitus trials with a reported enrollment target (98% lower).
The record links to 2 conditions, with Diabetes Mellitus appearing as the primary indexed condition, and to 3 interventions - of which Glargine insulin is the first listed.
NCT01810952 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT01810952 about?
NCT01810952 is a clinical study titled "The Management of Glucocorticoid-Induced Hyperglycemia in Hospitalized Patients". The investigators hypothesize that includes patient weight and glucocorticoid dose can be used to safely initiate insulin treatment in diabetic/hyperglycemic patients who are to be treated with pharmacological doses of glucocorticoids.
What is the current status of trial NCT01810952?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 37 participants. The study started on 2010-09. Estimated completion is 2013-09.
What conditions does trial NCT01810952 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Hyperglycemia.
What interventions are being tested in trial NCT01810952?
The interventions under investigation include: Glargine insulin (DRUG), Lispro insulin (DRUG), NPH Insulin (DRUG).
Who is sponsoring clinical trial NCT01810952?
This trial is sponsored by Baylor College of Medicine, which has 616 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01810952 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01810952's enrollment target sits among peer trials
37 170th of 208 higher than 37 of 208 other Diabetes Mellitus trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetes Mellitus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Impact GLP-1 Agonists Following Bariatric
RECRUITING · Phase 4
-
Oral Anti Diabetic Agents in the Hospital
ACTIVE NOT RECRUITING · Phase 4
-
People With CHC Who Achieved a Sustained Virological Response Following Therapy With Direct Acting Antiviral Agents
ACTIVE NOT RECRUITING · Phase 4
-
Impact of Empagliflozin on Functional Capacity in Heart Failure with Preserved Ejection Fraction
COMPLETED · Phase 4
-
Pioglitazone Study of Triglyceride Changes in Subjects With Type 2 Diabetes After Conversion From Rosiglitazone.
COMPLETED · Phase 4
-
A Study of Rapid-Acting Mealtime Insulin in Children and Adolescents With Newly Diagnosed Type 1 Diabetes Mellitus
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02800486 · 37 participants · Phase 2
Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
- NCT03173937 · 37 participants · Phase 1
Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome
- NCT03295227 · 37 participants · Phase 1
Pembrolizumab in Treating Participants With Unresectable Thymoma or Thymic Cancer
- NCT03401047 · 37 participants · Early Phase 1
Study to Assess Potential Impairments in Estradiol Augmentation of Gonadotropin Secretion in Polycystic Ovary Syndrome
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia